News

In a recently published study, Eric Ross from McLean Hospital and CHDS’ Djøra Soeteman showed that Esketamine can be cost-effective for patients with treatment-resistant depression if the price drops by

CHDS Post-Doctoral Fellow Allison Portnoy and Faculty Stéphane Verguet with others published an article in Value in Health about the two main delivery platforms of the measles vaccine

Survivors of childhood cancer previously treated with chest radiation are at high risk of developing secondary breast cancer. Similar to BRCA1 mutation carriers, an estimated 30% of these survivors will develop

On Thursday, July 16, 2020, the Learning Network for Countries in Transitions (LNCT) hosted a webinar discussion on the incremental costs of routine immunization, campaigns, and outreach services

The COVID-19 crisis has focused unprecedented attention on the use of benefit-cost analysis and approaches for valuing mortality risk reductions, commonly referred to as the

Lisa A. Robinson, Senior Research Scientist, was appointed CHDS Deputy Director on July 1, 2020. Robinson specializes in the conduct of benefit-cost analysis, particularly

CHDS faculty Nicolas Menzies received a 2020 Harvard Chan Mentoring Award. The award recognizes faculty who enhance their students’ experience by their guidance and support

Fangli Geng, 3rd-year doctoral student in Decision Sciences/Health Policy, chaired the organizing committee for “Global Symposium: Post-acute Care and Rehabilitation during COVID-19

Sue J. Goldie, CHDS Faculty Director and the Roger Irving Lee Professor of Public Health at the Harvard T.H. Chan School of Public Health, has been named the 2020 recipient of the

How to consider risk in personal decisions about re-opening? CHDS faculty Eve Wittenberg discussed the trade-offs inherent in risky decisions with WBUR’s reporter Carey Goldberg